BR9911291A - Diagnóstico diferencial de neurodegeneração - Google Patents

Diagnóstico diferencial de neurodegeneração

Info

Publication number
BR9911291A
BR9911291A BR9911291-4A BR9911291A BR9911291A BR 9911291 A BR9911291 A BR 9911291A BR 9911291 A BR9911291 A BR 9911291A BR 9911291 A BR9911291 A BR 9911291A
Authority
BR
Brazil
Prior art keywords
neurodegeneration
differential diagnosis
methods
quantification
relates
Prior art date
Application number
BR9911291-4A
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Andre Van Devoorde
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR9911291A publication Critical patent/BR9911291A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Eye Examination Apparatus (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"DIAGNóSTICO DIFERENCIAL DE NEURODEGENERAçãO". Apresente invenção se refere a novos processos para a detecçãoespecífica, quantificação e/ou diagnóstico diferencial deneurodegeneração em um indivíduo empregando um ensaio emcombinação que detecta pelo menos três marcadores neurológicosem um ou mais fluidos corporais do indivíduo, sendo o tipo e o graude degeneração um reflexo das alterações quantitativas no nívelde todos os marcadores em comparação com a amostra decontrole. A presente invenção também se refere a processos paraa detecção de Rab3a, SNAP25 e <244>-sinucleína no fluidocérebro-espinhal e ao emprego destes processos em um ensaio emcombinação para a detecção específica, quantificação e/oudiagnóstico diferencial de neurodegeneração.
BR9911291-4A 1998-07-03 1999-06-29 Diagnóstico diferencial de neurodegeneração BR9911291A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870148 1998-07-03
EP98870236 1998-11-03
EP99870069 1999-04-09
PCT/EP1999/004483 WO2000002053A2 (en) 1998-07-03 1999-06-29 Differential diagnosis of neurodegeneration

Publications (1)

Publication Number Publication Date
BR9911291A true BR9911291A (pt) 2001-12-04

Family

ID=27239769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911291-4A BR9911291A (pt) 1998-07-03 1999-06-29 Diagnóstico diferencial de neurodegeneração

Country Status (12)

Country Link
EP (1) EP1095278B1 (pt)
JP (3) JP2002519702A (pt)
CN (1) CN1316055A (pt)
AT (1) ATE312349T1 (pt)
AU (1) AU754062B2 (pt)
BR (1) BR9911291A (pt)
CA (1) CA2329523A1 (pt)
DE (1) DE69928809T2 (pt)
DK (1) DK1095278T3 (pt)
ES (1) ES2255280T3 (pt)
HK (1) HK1036834A1 (pt)
WO (1) WO2000002053A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002075317A2 (en) * 2001-03-15 2002-09-26 Novartis Ag Screening for drugs against disorders associated with schizophrenia
KR100506766B1 (ko) * 2001-11-20 2005-08-05 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및이를 포함하는 융합단백질
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
AT500321B1 (de) * 2003-12-30 2006-02-15 Red Bull Gmbh Verfahren zur diagnose des down-syndroms
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1827473A4 (en) * 2004-12-01 2009-08-19 Whitehead Biomedical Inst MODULATOR OF ALPHA SYNNUCLEINE TOXICITY
ES2535978T3 (es) * 2006-11-17 2015-05-19 Friedrich-Alexander-Universität Erlangen-Nürnberg Procedimiento para el diagnóstico diferencial de demencias
DK3067066T3 (da) * 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
JP2009052933A (ja) * 2007-08-24 2009-03-12 Rakuno Gakuen プリオン病の検出方法及び診断キット
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
US8501465B2 (en) 2007-12-21 2013-08-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
US20110159527A1 (en) * 2008-06-16 2011-06-30 Michael Gebhard Schlossmacher Methods and kits for diagnosing neurodegenerative disease
ES2541213T3 (es) * 2009-09-16 2015-07-16 United Arab Emirates University Agente de diagnóstico para la enfermedad de Parkinson
CA2784919A1 (en) 2010-01-26 2011-07-26 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2553466A4 (en) * 2010-04-01 2013-10-16 Banyan Biomarkers Inc MARKERS AND ASSAYS FOR DETECTING NEUROTOXICITY
GB201011420D0 (en) 2010-07-06 2010-08-18 United Arab Emirates Universit Method for diagnosis
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10942190B2 (en) 2014-01-21 2021-03-09 Shimadzu Corporation Measurement method for amyloid precursor protein cleavage peptides
ES2769048T3 (es) 2014-05-22 2020-06-24 Shimadzu Corp Biomarcador indirecto para evaluar la acumulación de péptido beta amiloide intracerebral y método para el análisis del mismo
BR112017004883A2 (pt) * 2014-09-10 2017-12-05 Abbvie Deutschland ensaio de diagnóstico baseado em fragmento de rgma
US11268965B2 (en) 2015-09-16 2022-03-08 Shimadzu Corporation Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
CA3044048A1 (en) * 2016-11-16 2018-05-24 Nanosomix, Inc. Quantification of subpopulations of exosomes and diagnosis of neurodegenerative disorders
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
GB201814807D0 (en) * 2018-09-12 2018-10-24 Univ Newcastle Dementia Biomarkers
EP3660509B1 (en) * 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies
CA3203308A1 (en) * 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease

Also Published As

Publication number Publication date
EP1095278B1 (en) 2005-12-07
JP2006091025A (ja) 2006-04-06
DE69928809T2 (de) 2006-08-31
DE69928809D1 (de) 2006-01-12
HK1036834A1 (en) 2002-01-18
DK1095278T3 (da) 2006-04-18
JP2002519702A (ja) 2002-07-02
JP4580455B2 (ja) 2010-11-10
JP2010019864A (ja) 2010-01-28
EP1095278A2 (en) 2001-05-02
AU754062B2 (en) 2002-10-31
WO2000002053A3 (en) 2000-02-24
AU5029099A (en) 2000-01-24
WO2000002053A2 (en) 2000-01-13
CN1316055A (zh) 2001-10-03
CA2329523A1 (en) 2000-01-13
ES2255280T3 (es) 2006-06-16
ATE312349T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
BR9911291A (pt) Diagnóstico diferencial de neurodegeneração
CY1115366T1 (el) Δεικτες ογκου
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
ATE406834T1 (de) System zur überwachung der konzentration von analyten in körperflüssigkeiten
WO2004063753A3 (en) A serum marker for measuring liver fibrosis
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
GB9506050D0 (en) Assaying collagen fragments in body fluids
DE50104561D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
ATE369564T1 (de) Differenzielles immunoassay für myoglobin
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
DK0720745T3 (da) Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker
ATE377192T1 (de) Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
WO2001083816A3 (en) Method for detecting tumors
BR9913770A (pt) Processo de ensaio para determinação da cobalamina ligada a transcobalamina ii (tcii) em uma amostra de corpo, kit para uso em um ensaio diagnóstico, e, uso de holo-tc ii
IL129766A0 (en) Immunohistochemical detection assay for carcinoma proliferative status
DK1664330T3 (da) Blod- og urintest
DK1297342T3 (da) Metode til diagnostisk bestemmelse af Alzheimer&#39;s sygdom på basis af holo-transcobalamin II
WO2001077670A3 (en) Homocysteine assay
PT1218749E (pt) Sistema de deteccao de cancro da prostata atraves da analise do psa/igf-l livre
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
ES2168378T3 (es) Determinacion de tripsinogeno-2 libre y en forma de complejo.
ATE229183T1 (de) Verfahren zur reihenuntersuchung auf prostatakrebs durch messung des apolipoprotein-d- spiegels in körperflüssigkeiten
EP1947459A3 (en) Differential immunoassay
WO2002043559A3 (en) Methods and kits for diagnosis of schizophrenia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5,6,7 E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.